Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model
doi: 10.1186/s13046-016-0353-8
Figure Lengend Snippet: In vitro effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on Hep3B and HuH7 human HCC cells and normal human liver (WRL68) cells. a Quantitative results of MTT assay showing the inhibitor effects on viability of Hep3B cells at 5 and 10 MOI (the multiplicity of infection) per virus; ( b ) Quantitative results of MTT assay showing the inhibitor effects on viability of HuH7 cells at 10 and 20 MOI per virus; and ( c ) Quantitative results of MTT assay showing the inhibitor effects on viability of WRL68 cells at 50 MOI per virus. Data are represented as mean ± SE. d Representatives of semi-quantitative assessment of cytotoxic potency by crystal violet cytopathic effect assay on Hep3B cells (left panel), HuH7 cells (middle panel), and WRL68 cells (right panel) at indicated MOIs. Ad-ΔB = non-armed control oncolytic adenovirus; Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (or Ad-ΔB/TRAIL+IL-12) = combined therapy with two oncolytic adenoviruses encoding human TRAIL and IL-12 genes, respectively
Article Snippet: The Hep3B human HCC cell line, the WRL68 human normal liver cell line, and the HEK293 human embryonic kidney cell line expressing the E1A region of Ad5 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), while the HuH7 human HCC cell line was obtained from Japan Health Science Research Resources (JCRB Genebank, Osaka, Japan).
Techniques: In Vitro, MTT Assay, Infection, Virus, Control